Lymphocytes matter. ALC count matters. Yet another paper in 2026 showing that when ALC levels fall from radiation, recurrence of cancer occurs. This progression free survival of ALC high vs ALC low is self explanatory. NK cells and T cells protect
https://t.co/4lAVD8UM65
Best of wishes Michael and Congratulations .
There are millions of patients with cancer worldwide who are in complete remission. The next frontier is to develop therapies strengthening the immune system to prevent recurrence in these over 15 million patients in the USA alone, and drive long term durable freedom from cancer to win the war. Incremental short term duration of response should no longer be an acceptable outcome.
The therapies to address and maintain cancer free status are now here……..the orchestration of the immune system, the identification of tumor DNA in the peripheral blood, the easy measurement of the NK and T cell levels in the peripheral blood count, the sophistication of next gen PET/ MRI/ CT scans, the ability to grow and store activated NK cells, the ability to identify tumor educated T cells, the new knowledge of camelid derived heavy chain single domain antibodies and the ability to precisely target radioactive ligands, to precisely target CART and CarNK and CAR-iNKT cells. These immunotherapy advances are all here today and in various stages of clinical trials. The oncology community will enter this next generation of paradigm change. The need to establish these diagnostic and therapeutic combinations as IMMUNOTHERAPY 2.0 is both urgent and exhilarating.
This was the subject of my one hour talk with NIH and NCI and the decade of collaboration with Jeffrey Schlom and James Gulley to develop a cancer vaccine. Hope to release the talk once I receive the video recording and obtain clearance to make it public. We are closer than ever.
Step up and save lives. Enforce right to try and get the FDA to stop cockblocking this treatment. @LoriMills4CA42@realDonaldTrump@RobertKennedyJr (BTW great CNN interview, but you need to be the calm in the room)
1 month ago I flew to DC to testify to the FDA asking them to unleash #ANKTIVA and NK cell therapy.
They are failing the American people.
Put Cryopreservation in all hospitals! @bullishbruk
Joe Rogan was stunned when Dr. Zach Bush explained how high fructose corn syrup is engineered to hijack the brain.
Bush said boxed apple juice with HFCS hits the frontal lobe the same way cocaine does. The molecule is flipped from natural fructose so the liver can’t process it as a carbohydrate. Instead, it treats it as an inflammatory triglyceride instead.
The result, he claims is cardiovascular disease, brain inflammation, anxiety, and depression.
@mckenzielaw Thank you for sharing your story. It hurts me to think that the medical community can come to such a consensus and the bureaucrats can block it. People are fed up with the government making decisions that go against the science. (The real science, not the Fauci-type science)...
@DrMakaryFDA How about you prove the FDA is not corrupt and in the pockets of #bigpharma and approve #Anktiva for #Lymphopenia. You can only suck up to big pharma for so long before the masses find a way to fly to another country to get this lifesaving approved #immunotherapy
Working to explain to the world how and why Bioshield works.
T cells and NK cells kill cancer, that’s irrefutable.
Low NK cells and T cells means cancer grows, that’s irrefutable.
So if there is a drug available to boost NK and T cells then there is better chance to kill the cancer cell of any tumor type – That’s the how and it is that simple.
1. NK and T cells (lymphocytes) kill cancer… causation
2. Anktiva proliferates, grows and activates NK and T cells in the body... causation (and in the FDA approved label)
3. Adding Anktiva to current standards of care have shown prolonged survival in patients with cancer across multiple tumor types since it is treating the immune system... causation.
That is the HOW!
Anktiva the Bioshield is the first immunotherapy in history of medicine that is FDA approved with a mechanism of action to grow and supercharge NK and T cells in the body, generate memory T cells and restore the immune system without stimulating immunosuppressive T cells.
Now what's next? We can measure low NK and T cells (lymphopenia) with a simple blood test (ALC). This is no different than the same test measuring low red blood cells (anemia) or low neutrophils (neutropenia). Low NK and T cells are called lymphopenia. Ask your doctor what is my ALC? (absolute lymphocyte count)
Today, FDA has approved EPOGEN to treat anemia regardless of cancer type and has approved NEUPOGEN to treat neutropenia regardless of cancer type. So, based on the mechanism of action of ANKTIVA and the irrefutable causation that NK cells and T cells kill cancer, ANKTIVA should be enabled to treat patients with low NK and T cells (lymphopenia) regardless of tumor type. Especially since ANKTIVA, by activating NK and T cells (reversing lymphopenia) is the only FDA APPROVED mechanism of action in the label to generate MEMORY T CELLS. This supercharging of the immune system happens regardless of the cancer type and we have now shown in completed clinical trials across multiple tumor types including lung cancer (NSCLC), small-cell lung cancer (SCLC), urothelial carcinoma, head and neck cancer, melanoma, colorectal cancer, cervical cancer, renal cell carcinoma, gastric cancer, and hepatocellular carcinoma (manuscript in progress) that by increasing NK and T cells, we induce prolonged survival in patients who have failed all standards of care including current immunotherapy with checkpoint inhibitors. This mechanism of action has already been approved showing long term complete responses, but approved only for an orphan state of a subset of bladder cancer.
So, if ANKTIVA could receive the same consideration as EPOGEN and NEUPOGEN as an immune supportive agent, many patients could benefit now without having to fly to LA. I hope we can change that quickly and change the lives of countless of desperate patients in which all standards of care have failed. Working hard to change the course of cancer everyday.
The paradigm change is we are treating the immune system, regardless of its cancer type. Cancer is the symptom and the collapse of the immune system is the root cause.
A devastating critique of modern oncology from a leading voice, Dr. Patrick Soon-Shiong.
He reveals a fundamental flaw in our 40-year war on cancer: the very treatments we hail as first-line defenses—chemotherapy and radiation—systematically destroy the patient's best long-term allies: their NK cells and T-cells.
We celebrate short-term "response rates" (tumor shrinkage) as victory. But this is a pyrrhic victory. By wiping out the immune system's memory and killing cells, we leave the body defenseless against metastasis, which is ultimately what kills most patients.
The tragedy is compounded by the solution. Dr. Soon-Shiong states we have the knowledge to change this paradigm now. The first step for any cancer patient should be to build and protect the immune system, not decimate it.
Yet, as his clinic receives over 10,000 desperate requests with only 30 available spots, he voices a profound despair. This life-saving approach remains inaccessible to the masses, locked away by a system resistant to change.
The solution, he insists, is not a distant dream. It could be made available to the nation "by a stroke of a pen." The knowledge exists. The failure is one of implementation, leaving thousands to a fate we have the power to prevent.
@PeterSchiff I appreciate your podcasts and it led me to buy GDXJ (a small amount) at ~$42. Being in Canada I was unable to get your EPGIX in my retirement account.
pancreatic and beyond. Biden had his shot and fumbled it—pouring billions into half-measures while families suffered. History won't forgive hesitation. But you? You're the fighter America needs. #cancer#immunity
Dear President Trump, it's time to make history, not just headlines. Your legacy is about saving lives on a scale that echoes through generations. BioShield, the revolutionary Cancer BioShield platform from ImmunityBio—powered by the FDA-approved Anktiva—holds the key #trump
to restoring the immune system and potentially curing cancers that have plagued humanity for too long. Unlike the old ways that tear down the body's defenses, BioShield rebuilds them, fighting lymphopenia head-on and turning the tide against solid tumors, from bladder to